€2.6 -0.1 -4.2%
Last Trade - 26/10/20
| Market Cap | ÂŁ135.2m |
| Enterprise Value | ÂŁ-50.9m |
| Revenue | ÂŁ12.4m |
| Position in Universe | 439th / 850 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.76 | 6.17 | 9.08 | 11.9 | 14.5 | 13.1 | 14.0 | 16.4 | +22.5% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | March 1, 2002 |
| Public Since | March 29, 2012 |
| No. of Shareholders: | n/a |
| No. of Employees: | 311 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | CAC Mid & Small , CAC Small , CAC All-tradable , Enternext Pea-pme 150 , |
| Exchange | Euronext - Paris |
| Shares in Issue | 54,874,086 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 177-181 avenue Pierre Brossolette, MONTROUGE, 92120, France |
| Web | https://www.dbv-technologies.com/ |
| Phone | +33 1 55427878 |
| Contact | Sara Sherman (Senior Director - Investor Relations and Strategy) |
| Auditors | Deloitte & Associes |
As of 26/10/20, shares in DBV Technologies SA are trading at €2.6, giving the company a market capitalisation of £135.2m. This share price information is delayed by 15 minutes.
Shares in DBV Technologies SA are currently trading at €2.6 and the price has moved by -78.56% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the DBV Technologies SA price has moved by -75.96% over the past year.
Of the analysts with advisory recommendations for DBV Technologies SA, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for DBV Technologies SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
DBV Technologies SA is scheduled to issue upcoming financial results on the following dates:
DBV Technologies SA does not currently pay a dividend.
DBV Technologies SA does not currently pay a dividend.
DBV Technologies SA does not currently pay a dividend.
To buy shares in DBV Technologies SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in DBV Technologies SA are currently trading at €2.6, giving the company a market capitalisation of £135.2m.
Here are the trading details for DBV Technologies SA:
Based on an overall assessment of its quality, value and momentum, DBV Technologies SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in DBV Technologies SA are currently priced at €2.6. At that level they are trading at 0.214% discount to the analyst consensus target price of 0.00.
Analysts covering DBV Technologies SA currently have a consensus Earnings Per Share (EPS) forecast of -3.247 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DBV Technologies SA. Over the past six months, the relative strength of its shares against the market has been -73.7%. At the current price of €2.6, shares in DBV Technologies SA are trading at -70.25% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for DBV Technologies SA.
DBV Technologies SA's management team is headed by:
Here are the top five shareholders of DBV Technologies SA based on the size of their shareholding:
